title: Intranasal Abuse Potential, Pharmacokinetics, and Safety of Once-Daily, Single-Entity, Extended-Release Hydrocodone (HYD) in Recreational Opioid Users.
abstract: A once-daily, extended-release hydrocodone bitartrate tablet with abuse-deterrent properties (Hysingla ER® [HYD]) is available for the treatment of chronic pain in appropriate patients. This study evaluated the intranasal abuse potential and pharmacokinetics of HYD coarse and fine particles vs hydrocodone powder or placebo.
  
  
  
  Single-center, double-blind, positive- and placebo-controlled, randomized, four-treatment crossover study.
  
  
  
  Healthy adult, nondependent, recreational opioid users with a history of intranasal abuse.
  
  
  
  During four treatment periods, subjects (N = 31) received hydrocodone powder 60 mg, HYD coarse particles 60 mg, HYD fine particles 60 mg, or placebo, with five-to-seven-day washouts between treatments. Measures over 36 hours postdose included drug-liking and willingness to take drug again, assessed using visual analog scales (VASs), pupillometry, intranasal irritation, and pharmacokinetics.
  
  
  
  Insufflation of both HYD coarse and fine particles led to lower "At this Moment" Drug Liking VAS peak values compared with hydrocodone powder, but higher values compared with placebo (P < 0.001 for all comparisons). Similar results were observed for Overall Drug Liking VAS, Take Drug Again VAS, and Subjective Drug Value. Compared with hydrocodone, insufflation of HYD particles led to reduced miosis and increased nasal irritation. Mean hydrocodone Cmax following insufflation of HYD coarse particles, HYD fine particles, and hydrocodone powder was 27.5, 36.5, and 105.8 ng/mL, respectively; median Tmax was ≥2-fold longer with either HYD particle size than hydrocodone powder; and (Cmax/Tmax) was 9.5, 13.4, and 82.0 ng/mL/h, respectively. Safety was consistent with that of opioid agonists.
  
  
  
  HYD demonstrated reduced intranasal abuse potential compared with hydrocodone powder.
authors.affiliation: *Purdue Pharma L.P., Stamford, Connecticut, USA; stephen.harris@pharma.com.
authors.forename: Stephen C
authors.initials: SC
authors.lastname: Harris
authors.affiliation: *Purdue Pharma L.P., Stamford, Connecticut, USA;
authors.forename: Alessandra
authors.initials: A
authors.lastname: Cipriano
authors.affiliation: *Purdue Pharma L.P., Stamford, Connecticut, USA;
authors.forename: Salvatore V
authors.initials: SV
authors.lastname: Colucci
authors.affiliation: *Purdue Pharma L.P., Stamford, Connecticut, USA;
authors.forename: Ram P
authors.initials: RP
authors.lastname: Kapil
authors.affiliation: INC Research Toronto, Toronto, Ontario, Canada.
authors.forename: Pierre
authors.initials: P
authors.lastname: Geoffroy
authors.affiliation: INC Research Toronto, Toronto, Ontario, Canada.
authors.forename: Talar
authors.initials: T
authors.lastname: Hopyan
authors.affiliation: INC Research Toronto, Toronto, Ontario, Canada.
authors.forename: Naama
authors.initials: N
authors.lastname: Levy-Cooperman
mesh_terms: D000281:Administration, Intranasal; D000328:Adult; D000701:Analgesics, Opioid / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D018592:Cross-Over Studies; D003692:Delayed-Action Preparations / Q000008:administration & dosage / Q000493:pharmacokinetics; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D006853:Hydrocodone / Q000008:administration & dosage* / Q000493:pharmacokinetics*; D013287:Illicit Drugs / Q000493:pharmacokinetics*; D008297:Male; D008875:Middle Aged; D009293:Opioid-Related Disorders / Q000175:diagnosis / Q000378:metabolism*; D011208:Powders; D055815:Young Adult
chemical_list: D000701:Analgesics, Opioid; D003692:Delayed-Action Preparations; D013287:Illicit Drugs; D011208:Powders; D006853:Hydrocodone
keywords: Abuse Deterrent; Abuse Potential; HYD; Hydrocodone; Pain
references.citation: Clin J Pain. 2008 Jul-Aug;24(6):521-7
references.pmid: 18574361
references.citation: Hepatology. 2007 Oct;46(4):966-70
references.pmid: 17894320
references.citation: Curr Rheumatol Rep. 2008 Jan;10(1):11-8
references.pmid: 18457606
references.citation: Drug Alcohol Depend. 2008 Dec 1;98(3):191-202
references.pmid: 18606504
references.citation: Pain Physician. 2014 Mar-Apr;17(2):E119-28
references.pmid: 24658483
references.citation: Clin Ther. 2001 Aug;23(8):1296-310
references.pmid: 11558866
references.citation: Am J Drug Alcohol Abuse. 2011 Jul;37(4):205-17
references.pmid: 21517709
references.citation: J Psychopharmacol. 2013 Sep;27(9):808-16
references.pmid: 23784739
references.citation: Harm Reduct J. 2009 May 29;6:8
references.pmid: 19480676
references.citation: Psychopharmacology (Berl). 1992;107(2-3):352-8
references.pmid: 1615136
references.citation: Pain Physician. 2008 Mar;11(2 Suppl):S105-20
references.pmid: 18443635
references.citation: J Natl Compr Canc Netw. 2003 Jul;1(3):423-8
references.pmid: 19761073
references.citation: Pain Physician. 2012 Jul;15(3 Suppl):ES67-92
references.pmid: 22786463
references.citation: Ann Intern Med. 2002 Dec 17;137(12):947-54
references.pmid: 12484709
references.citation: Pain. 2012 Oct;153(10):1997-2008
references.pmid: 22770841
references.citation: Lancet. 2012 Jan 7;379(9810):55-70
references.pmid: 22225671
references.citation: J Pain. 2013 Apr;14(4):351-8
references.pmid: 23127293
references.citation: Lancet. 2013 Nov 9;382(9904):1564-74
references.pmid: 23993281
references.citation: Drugs. 2010 Sep 10;70(13):1657-75
references.pmid: 20731474
references.citation: Harm Reduct J. 2011 Oct 19;8:29
references.pmid: 22011626